Early tolerability of Comirnaty vaccine in patients with chronic neurological diseases.
Rev Neurol (Paris)
; 177(10): 1262-1265, 2021 Dec.
Article
in English
| MEDLINE | ID: covidwho-1466808
ABSTRACT
Patients with chronic neurological diseases may have predisposing risk factors for severe COVID-19 and should be considered as priority candidates for SARS-CoV-2 vaccination. Nevertheless, the safety of RNA vaccine was evaluated in healthy volunteers or in patients with stable chronic medical conditions excluding patients with chronic neurological diseases. We report here the early tolerability of Comirnaty vaccine in 36 patients with chronic neurological diseases and demonstrate good early tolerability, better than found in healthy people in phase 3 trials.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19 Vaccines
/
COVID-19
Type of study:
Experimental Studies
/
Prognostic study
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
Rev Neurol (Paris)
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS